Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jarrod Marto, Ph.D.

Co-Author

This page shows the publications co-authored by Jarrod Marto and Nathanael Gray.
Connection Strength

6.140
  1. PRM-LIVE with Trapped Ion Mobility Spectrometry and Its Application in Selectivity Profiling of Kinase Inhibitors. Anal Chem. 2021 Oct 04.
    View in: PubMed
    Score: 0.249
  2. Exploring Ligand-Directed N-Acyl-N-alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degrader Development. ACS Med Chem Lett. 2021 Aug 12; 12(8):1302-1307.
    View in: PubMed
    Score: 0.246
  3. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. Eur J Med Chem. 2021 Oct 05; 221:113481.
    View in: PubMed
    Score: 0.242
  4. Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Med Chem Lett. 2020 Nov 12; 11(11):2238-2243.
    View in: PubMed
    Score: 0.233
  5. Discovery of Covalent MKK4/7 Dual Inhibitor. Cell Chem Biol. 2020 12 17; 27(12):1553-1560.e8.
    View in: PubMed
    Score: 0.232
  6. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. J Med Chem. 2020 07 09; 63(13):6708-6726.
    View in: PubMed
    Score: 0.228
  7. Identification of a potent and selective covalent Pin1 inhibitor. Nat Chem Biol. 2020 09; 16(9):979-987.
    View in: PubMed
    Score: 0.227
  8. Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. J Med Chem. 2020 05 14; 63(9):4880-4895.
    View in: PubMed
    Score: 0.226
  9. Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface. ACS Med Chem Lett. 2020 Jun 11; 11(6):1269-1273.
    View in: PubMed
    Score: 0.225
  10. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chem Biol. 2020 05 21; 27(5):525-537.e6.
    View in: PubMed
    Score: 0.223
  11. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. J Med Chem. 2020 02 27; 63(4):1624-1641.
    View in: PubMed
    Score: 0.222
  12. Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. ACS Med Chem Lett. 2020 Mar 12; 11(3):346-352.
    View in: PubMed
    Score: 0.218
  13. Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14. Bioorg Med Chem Lett. 2019 08 01; 29(15):1985-1993.
    View in: PubMed
    Score: 0.212
  14. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chem Biol. 2019 06 20; 26(6):818-829.e9.
    View in: PubMed
    Score: 0.210
  15. Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. Cell Chem Biol. 2019 06 20; 26(6):804-817.e12.
    View in: PubMed
    Score: 0.209
  16. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019 06 20; 26(6):792-803.e10.
    View in: PubMed
    Score: 0.209
  17. A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification. J Am Chem Soc. 2019 01 09; 141(1):191-203.
    View in: PubMed
    Score: 0.205
  18. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chem Biol. 2018 04 19; 25(4):460-470.e6.
    View in: PubMed
    Score: 0.194
  19. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chem Biol. 2017 Aug 17; 24(8):1005-1016.e3.
    View in: PubMed
    Score: 0.187
  20. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017 02 01; 25(3):838-846.
    View in: PubMed
    Score: 0.179
  21. Leveraging Gas-Phase Fragmentation Pathways for Improved Identification and Selective Detection of Targets Modified by Covalent Probes. Anal Chem. 2016 12 20; 88(24):12248-12254.
    View in: PubMed
    Score: 0.178
  22. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 10; 12(10):876-84.
    View in: PubMed
    Score: 0.175
  23. Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem. 2015 Aug 27; 58(16):6589-606.
    View in: PubMed
    Score: 0.163
  24. Development of small molecules targeting the pseudokinase Her3. Bioorg Med Chem Lett. 2015 Aug 15; 25(16):3382-9.
    View in: PubMed
    Score: 0.160
  25. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol. 2014 Dec; 10(12):1006-12.
    View in: PubMed
    Score: 0.154
  26. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31; 511(7511):616-20.
    View in: PubMed
    Score: 0.150
  27. Protected amine labels: a versatile molecular scaffold for multiplexed nominal mass and sub-Da isotopologue quantitative proteomic reagents. J Am Soc Mass Spectrom. 2014 Apr; 25(4):636-50.
    View in: PubMed
    Score: 0.147
  28. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014 Jan 03; 53(1):199-204.
    View in: PubMed
    Score: 0.144
  29. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27; 19(1):140-54.
    View in: PubMed
    Score: 0.127
  30. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nat Chem Biol. 2021 09; 17(9):954-963.
    View in: PubMed
    Score: 0.061
  31. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 01 13; 37(1):104-122.e12.
    View in: PubMed
    Score: 0.055
  32. STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. Elife. 2020 Jan 08; 9.
    View in: PubMed
    Score: 0.055
  33. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chem Biol. 2018 08 16; 25(8):1006-1016.e8.
    View in: PubMed
    Score: 0.050
  34. Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chem Biol. 2018 02 15; 25(2):135-142.e5.
    View in: PubMed
    Score: 0.048
  35. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A. 2014 Jun 17; 111(24):8895-900.
    View in: PubMed
    Score: 0.037
  36. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011 Jun 10; 332(6035):1317-22.
    View in: PubMed
    Score: 0.030
  37. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010 Dec 01; 70(23):9827-36.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.